Drug of Choice for SVT in LV Dysfunction
Adenosine is the drug of choice for acute supraventricular tachycardia in patients with left ventricular dysfunction. 1
Rationale and Treatment Algorithm
First-Line: Adenosine
- Adenosine terminates SVT in approximately 95% of cases and has minimal negative inotropic effects, making it safe in heart failure 1, 2
- Administered as rapid IV bolus: 6 mg initially, then 12 mg if needed
- Extremely short half-life (seconds) minimizes risk of hemodynamic compromise
- Success rate of 78-96% across multiple studies 2
Critical Contraindication: Avoid Calcium Channel Blockers
Diltiazem and verapamil should be avoided in patients with suspected systolic heart failure 1. The guidelines explicitly state this contraindication multiple times because:
- These agents have significant negative inotropic effects
- Can precipitate fulminant acute heart failure 3
- Risk of hemodynamic collapse and ventricular fibrillation in compromised patients
- While effective in stable patients (80-98% success), the risk outweighs benefit in LV dysfunction
Second-Line Options
If adenosine fails or is contraindicated:
Intravenous beta-blockers are reasonable alternatives 1
- Excellent safety profile
- Less effective than adenosine but safer than calcium channel blockers in heart failure
- Esmolol preferred due to short half-life
Intravenous amiodarone may be considered when other therapies fail 1, 4
- Particularly in patients with borderline cardiac output
- Effective for VT suppression in structural heart disease
- No significant short-term toxicity with acute use
Hemodynamically Unstable Patients
Synchronized cardioversion is mandatory if the patient shows hypotension, altered mental status, shock, chest pain, or acute heart failure symptoms 1
- Should be performed immediately if adenosine fails
- Don't delay with multiple drug trials in unstable patients
Common Pitfalls to Avoid
- Never use verapamil or diltiazem in LV dysfunction - this is the most dangerous error
- Don't confuse SVT with pre-excited AF or VT (where calcium channel blockers can cause ventricular fibrillation)
- Ensure IV access is proximal for adenosine administration
- Have cardioversion equipment immediately available when giving adenosine
The evidence strongly supports adenosine as first-line specifically because it lacks the hemodynamic compromise risk that calcium channel blockers pose in heart failure patients 1, 2, 5.